Exposure should have taken place during the second or third trimester of pregnancy
The widespread adoption of long-acting GLP-1 therapies for both type 2 diabetes and obesity has placed significant pressure on global supply chains, resulting in recurring product shortages across multiple regions
Disclaimer: The following information is provided strictly for educational and informational
As an example of a combined GLP-1 + FIM intervention, eligible patients could receive both GLP-1 therapy and a FIM intervention emphasizing foods to support weight maintenance, reduce side effects, minimize loss of muscle and bone mass, and promote nutrient adequacy
This guide breaks down exactly how cagrilintide works for weight loss (amylin mechanisms), clinical trial results and real-world weight loss data, complete dosing protocols from beginner to advanced, side effects and management strategies, comparing cagrilintide to GLP-1 agonists and other weight loss peptides, combination strategies for maximum results, and sourcing considerations for this investigational peptide